Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
ResMed Analyst Ratings and Price Targets | NYSE:RMD | Benzinga
ResMed Inc has a consensus price target of $244.2 based on the ratings of 19 analysts. The high is $290 issued by JP Morgan on April 24, 2025. The low is $169 issued by Morgan Stanley on October 27, 2023. The 3 most-recent analyst ratings were released by RBC Capital, UBS, and JP Morgan on April 24, 2025, respectively. With an average price target of $276.67 between RBC Capital, UBS, and JP Morgan, there's an implied 12.20% upside for ResMed Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
UBS
JP Morgan
Piper Sandler
Keybanc
1calculated from analyst ratings
Analyst Ratings for ResMed
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/24/2025 | Buy Now | 3.41% | RBC Capital | Craig Wong-Pan68% | $247 → $255 | Maintains | Sector Perform | Get Alert |
| 04/24/2025 | Buy Now | 15.58% | UBS | Laura Sutcliffe46% | $290 → $285 | Maintains | Buy | Get Alert |
| 04/24/2025 | Buy Now | 17.61% | JP Morgan | David Low52% | $286 → $290 | Maintains | Overweight | Get Alert |
| 04/24/2025 | Buy Now | 0.58% | Piper Sandler | Adam Maeder63% | $260 → $248 | Maintains | Neutral | Get Alert |
| 04/24/2025 | Buy Now | 11.12% | Keybanc | Brett Fishbin54% | $269 → $274 | Maintains | Overweight | Get Alert |
| 04/21/2025 | Buy Now | 9.09% | Keybanc | Tim Rezvan43% | $280 → $269 | Maintains | Overweight | Get Alert |
| 03/05/2025 | Buy Now | — | Citigroup | Mathieu Chevrier58% | — | Upgrade | Neutral → Buy | Get Alert |
| 03/05/2025 | Buy Now | -2.67% | Stifel | Jonathan Block72% | $250 → $240 | Maintains | Hold | Get Alert |
| 01/31/2025 | Buy Now | 15.99% | JP Morgan | David Low52% | $270 → $286 | Maintains | Overweight | Get Alert |
| 01/31/2025 | Buy Now | 13.55% | Keybanc | Brett Fishbin54% | $266 → $280 | Maintains | Overweight | Get Alert |
| 01/31/2025 | Buy Now | 5.44% | Piper Sandler | Adam Maeder63% | $252 → $260 | Maintains | Neutral | Get Alert |
| 01/31/2025 | Buy Now | — | Needham | Mike Matson45% | — | Reiterates | Hold → Hold | Get Alert |
| 01/10/2025 | Buy Now | 2.2% | Piper Sandler | Adam Maeder63% | → $252 | Initiates | → Neutral | Get Alert |
| 12/13/2024 | Buy Now | 1.39% | Stifel | Jonathan Block72% | → $250 | Initiates | → Hold | Get Alert |
| 10/25/2024 | Buy Now | -5.91% | RBC Capital | Craig Wong-Pan68% | $224 → $232 | Maintains | Sector Perform | Get Alert |
| 10/25/2024 | Buy Now | 7.88% | Keybanc | Brett Fishbin54% | $251 → $266 | Maintains | Overweight | Get Alert |
| 10/25/2024 | Buy Now | 14.77% | Baird | Joe Vruwink50% | $280 → $283 | Maintains | Outperform | Get Alert |
| 10/25/2024 | Buy Now | — | Needham | Mike Matson45% | — | Reiterates | → Hold | Get Alert |
| 10/01/2024 | Buy Now | -9.16% | RBC Capital | Craig Wong-Pan68% | $206 → $224 | Maintains | Sector Perform | Get Alert |
| 10/01/2024 | Buy Now | — | Needham | Mike Matson45% | — | Reiterates | → Hold | Get Alert |
| 09/26/2024 | Buy Now | 9.5% | B of A Securities | Lyanne Harrison51% | $240 → $270 | Maintains | Buy | Get Alert |
| 09/24/2024 | Buy Now | 13.55% | Baird | Joe Vruwink50% | → $280 | Initiates | → Outperform | Get Alert |
| 09/18/2024 | Buy Now | — | Needham | Mike Matson45% | — | Reiterates | → Hold | Get Alert |
| 09/18/2024 | Buy Now | -27% | Wolfe Research | Mike Polark41% | → $180 | Downgrade | Peer Perform → Underperform | Get Alert |
| 09/04/2024 | Buy Now | -4.29% | Needham | Mike Matson45% | → $236 | Downgrade | Buy → Hold | Get Alert |
| 08/02/2024 | Buy Now | -16.46% | RBC Capital | Craig Wong-Pan68% | $204 → $206 | Maintains | Sector Perform | Get Alert |
| 08/02/2024 | Buy Now | 1.79% | Keybanc | Brett Fishbin54% | $238 → $251 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | -4.29% | Needham | Mike Matson45% | $236 → $236 | Reiterates | Buy → Buy | Get Alert |
| 07/23/2024 | Buy Now | -17.27% | RBC Capital | Craig Wong-Pan68% | $200 → $204 | Maintains | Sector Perform | Get Alert |
| 06/25/2024 | Buy Now | — | Oppenheimer | Suraj Kalia21% | — | Downgrade | Outperform → Perform | Get Alert |
| 06/24/2024 | Buy Now | — | Citigroup | Mathieu Chevrier58% | — | Downgrade | Buy → Neutral | Get Alert |
| 06/24/2024 | Buy Now | -4.29% | Needham | Mike Matson45% | $236 → $236 | Reiterates | Buy → Buy | Get Alert |
| 04/26/2024 | Buy Now | -18.89% | Oppenheimer | Suraj Kalia21% | $205 → $200 | Maintains | Outperform | Get Alert |
| 04/26/2024 | Buy Now | -18.89% | RBC Capital | Craig Wong-Pan68% | $187 → $200 | Maintains | Sector Perform | Get Alert |
| 04/26/2024 | Buy Now | -3.48% | Keybanc | Brett Fishbin54% | $227 → $238 | Maintains | Overweight | Get Alert |
| 04/26/2024 | Buy Now | -4.29% | Needham | Mike Matson45% | $224 → $236 | Maintains | Buy | Get Alert |
| 04/01/2024 | Buy Now | -9.16% | Needham | Mike Matson45% | $215 → $224 | Maintains | Buy | Get Alert |
| 03/27/2024 | Buy Now | -12.81% | Mizuho | Anthony Petrone66% | $215 → $215 | Maintains | Buy | Get Alert |
| 02/06/2024 | Buy Now | -7.94% | Keybanc | Brett Fishbin54% | → $227 | Initiates | → Overweight | Get Alert |
| 01/30/2024 | Buy Now | -16.86% | Oppenheimer | Suraj Kalia21% | $185 → $205 | Maintains | Outperform | Get Alert |
| 01/30/2024 | Buy Now | -12.81% | Mizuho | Anthony Petrone66% | $195 → $215 | Maintains | Buy | Get Alert |
| 01/26/2024 | Buy Now | -20.92% | Mizuho | Anthony Petrone66% | $180 → $195 | Maintains | Buy | Get Alert |
| 01/25/2024 | Buy Now | -26.19% | RBC Capital | Craig Wong-Pan68% | $181 → $182 | Maintains | Sector Perform | Get Alert |
| 01/25/2024 | Buy Now | -27% | UBS | Saul Hadassin66% | $175 → $180 | Maintains | Neutral | Get Alert |
| 01/25/2024 | Buy Now | -12.81% | Needham | Mike Matson45% | $180 → $215 | Maintains | Buy | Get Alert |
| 01/09/2024 | Buy Now | -20.92% | JP Morgan | David Low52% | $160 → $195 | Maintains | Overweight | Get Alert |
| 10/31/2023 | Buy Now | -35.11% | Mizuho | Anthony Petrone66% | $180 → $160 | Maintains | Buy | Get Alert |
| 10/27/2023 | Buy Now | -31.46% | Morgan Stanley | Sean Laaman73% | → $169 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/16/2023 | Buy Now | -29.03% | Oppenheimer | Suraj Kalia21% | $275 → $175 | Maintains | Outperform | Get Alert |
| 10/12/2023 | Buy Now | -18.08% | RBC Capital | Craig Wong-Pan68% | $273 → $202 | Downgrade | Outperform → Sector Perform | Get Alert |
| 09/29/2023 | Buy Now | — | Wolfe Research | Mike Polark41% | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 09/18/2023 | Buy Now | -6.72% | B of A Securities | Lyanne Harrison51% | $250 → $230 | Maintains | Buy | Get Alert |
| 09/13/2023 | Buy Now | -27% | Mizuho | Anthony Petrone66% | $255 → $180 | Maintains | Buy | Get Alert |
| 09/06/2023 | Buy Now | -27% | Needham | Mike Matson45% | → $180 | Upgrade | Hold → Buy | Get Alert |
| 09/05/2023 | Buy Now | -31.06% | UBS | Saul Hadassin66% | $265 → $170 | Downgrade | Buy → Neutral | Get Alert |
| 08/14/2023 | Buy Now | 10.71% | RBC Capital | Craig Wong-Pan68% | $284 → $273 | Maintains | Outperform | Get Alert |
| 08/04/2023 | Buy Now | 15.18% | RBC Capital | Craig Wong-Pan68% | → $284 | Reiterates | Outperform → Outperform | Get Alert |
| 08/04/2023 | Buy Now | 1.39% | B of A Securities | Lyanne Harrison51% | $260 → $250 | Maintains | Buy | Get Alert |
| 08/04/2023 | Buy Now | 5.44% | Keybanc | Matthew Mishan55% | $280 → $260 | Maintains | Overweight | Get Alert |
| 08/01/2023 | Buy Now | 15.18% | RBC Capital | Craig Wong-Pan68% | $262 → $284 | Upgrade | Sector Perform → Outperform | Get Alert |
| 05/22/2023 | Buy Now | 17.61% | UBS | Saul Hadassin66% | → $290 | Initiates | → Buy | Get Alert |
| 04/14/2023 | Buy Now | 3.41% | Mizuho | Anthony Petrone66% | → $255 | Initiates | → Buy | Get Alert |
| 04/13/2023 | Buy Now | 3.41% | Mizuho | Anthony Petrone66% | → $255 | Initiates | → Buy | Get Alert |
| 01/27/2023 | Buy Now | 5.44% | JP Morgan | David Low52% | $245 → $260 | Maintains | Overweight | Get Alert |
| 01/17/2023 | Buy Now | -0.64% | JP Morgan | David Low52% | → $245 | Upgrade | Neutral → Overweight | Get Alert |
| 10/28/2022 | Buy Now | 3.01% | RBC Capital | Craig Wong-Pan68% | $252 → $254 | Maintains | Sector Perform | Get Alert |
| 10/28/2022 | Buy Now | 13.55% | Keybanc | Matthew Mishan55% | $276 → $280 | Maintains | Overweight | Get Alert |
| 10/20/2022 | Buy Now | 5.44% | B of A Securities | Lyanne Harrison51% | $245 → $260 | Upgrade | Neutral → Buy | Get Alert |
| 10/12/2022 | Buy Now | -0.64% | Jefferies | Matthew Taylor76% | → $245 | Initiates | → Hold | Get Alert |
| 09/08/2022 | Buy Now | — | Citigroup | John Deakin-Bell25% | — | Upgrade | Neutral → Buy | Get Alert |
| 08/12/2022 | Buy Now | — | JP Morgan | David Low52% | — | Downgrade | Overweight → Neutral | Get Alert |
| 08/12/2022 | Buy Now | 2.2% | RBC Capital | Craig Wong-Pan68% | $246 → $252 | Downgrade | Outperform → Sector Perform | Get Alert |
| 06/15/2022 | Buy Now | 0.17% | RBC Capital | Craig Wong-Pan68% | $244 → $247 | Maintains | Outperform | Get Alert |
| 06/06/2022 | Buy Now | -1.05% | RBC Capital | Craig Wong-Pan68% | $233 → $244 | Upgrade | Sector Perform → Outperform | Get Alert |
FAQ
What is the target price for ResMed (RMD) stock?
The latest price target for ResMed (NYSE:RMD) was reported by RBC Capital on April 24, 2025. The analyst firm set a price target for $255.00 expecting RMD to rise to within 12 months (a possible 3.41% upside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ResMed (RMD)?
The latest analyst rating for ResMed (NYSE:RMD) was provided by RBC Capital, and ResMed maintained their sector perform rating.
When was the last upgrade for ResMed (RMD)?
The last upgrade for ResMed Inc happened on March 5, 2025 when Citigroup raised their price target to N/A. Citigroup previously had a neutral for ResMed Inc.
When was the last downgrade for ResMed (RMD)?
The last downgrade for ResMed Inc happened on September 18, 2024 when Wolfe Research changed their price target from N/A to $180 for ResMed Inc.
When is the next analyst rating going to be posted or updated for ResMed (RMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ResMed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ResMed was filed on April 24, 2025 so you should expect the next rating to be made available sometime around April 24, 2026.
Is the Analyst Rating ResMed (RMD) correct?
While ratings are subjective and will change, the latest ResMed (RMD) rating was a maintained with a price target of $247.00 to $255.00. The current price ResMed (RMD) is trading at is $246.58, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
